SPC Logo

Pandemrix suspension and emulsion for emulsion for injection

Last Updated on eMC 01-Aug-2013 View changes  | GlaxoSmithKline UK Contact details

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. Name of the medicinal product

Pandemrix suspension and emulsion for emulsion for injection.

Influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)

2. Qualitative and quantitative composition

After mixing, 1 dose (0.5 ml) contains:

Split influenza virus, inactivated, containing antigen* equivalent to:

A/California/07/2009 (H1N1) derived strain used NYMC X-179A

3.75 micrograms**

* propagated in eggs

** haemagglutinin

AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)

The suspension and emulsion, once mixed, form a multidose vaccine in a vial. See section 6.5 for the number of doses per vial.

Excipient with known effect:

The vaccine contains 5 micrograms thiomersal

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Suspension and emulsion for emulsion for injection.

The suspension is a colourless light opalescent liquid.

The emulsion is a whitish homogeneous liquid.

4. Clinical particulars
4.1 Therapeutic indications

Prophylaxis of influenza caused by A (H1N1)v 2009 virus. In persons under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary (see sections 4.4 and 4.8).

Pandemrix should be used in accordance with Official Guidance.

4.2 Posology and method of administration

Posology

The dose recommendations take into account the safety and immunogenicity data from clinical studies in healthy subjects

See sections 4.4, 4.8 and 5.1 for details.

No data are available in children aged less than 6 months.

Adults aged 18 years and older:

One dose of 0.5 ml at an elected date.

Immunogenicity data obtained at three weeks after one dose of Pandemrix (H1N1)v suggest that a single dose may be sufficient.

If a second dose is administered there should be an interval of at least three weeks between the first and the second dose.

See section 5.1 regarding immune responses to one and two doses of Pandemrix (H1N1)v, including antibody levels after 6 and 12 months.

Paediatric population

Children and adolescents aged 10-17 years

Dosing may be in accordance with the recommendations for adults.

Children aged from 6 months to 9 years

One dose of 0.25 ml at an elected date.

There is a further immune response to a second dose of 0.25 ml administered after an interval of three weeks.

The use of a second dose should take into consideration the information provided in sections 4.4, 4.8 and 5.1.

Children aged less than 6 months

No data are available.

It is recommended that subjects who receive a first dose of Pandemrix should complete the vaccination course with Pandemrix (see section 4.4).

Method of administration

Immunisation should be carried out by intramuscular injection preferably into the deltoid muscle or anterolateral thigh (depending on the muscle mass).

For instructions on mixing of the medicinal product before administration, see section 6.6.

4.3 Contraindications

History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate and sodium deoxycholate) of this vaccine.

Immunisation should be postponed in subjects with a severe febrile illness or acute infection.

4.4 Special warnings and precautions for use

The vaccine can only be expected to protect against influenza caused by A/California/07/2009 (H1N1)v-like strains.

Caution is needed when administering this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1, to thiomersal and to residues (egg and chicken protein, ovalbumin, formaldehyde, gentamicin sulphate and sodium deoxycholate).

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Pandemrix should under no circumstances be administered intravascularly.

There are no data with Pandemrix using the subcutaneous route. Therefore, healthcare providers need to assess the benefits and potential risks of administering the vaccine in individuals with thrombocytopenia or any bleeding disorder that would contraindicate intramuscular injection unless the potential benefit outweighs the risk of bleedings.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

A protective immune response may not be elicited in all vaccinees (see section 5.1).

There are no safety, immunogenicity or efficacy data to support interchangeability of Pandemrix with other (H1N1)v vaccines.

Paediatric population

There are no safety and immunogenicity data available from clinical studies with Pandemrix (H1N1)v in children aged less than 6 months. Vaccination is not recommended in this age group.

In children aged 6 to 35 months (N=51) who received two doses of 0.25 ml (half of the adult dose) with an interval of 3 weeks between doses there was an increase in the rates of injection site reactions and general symptoms after the second dose (see section 4.8). In particular rates of fever (axillary temperature ≥38°C) increased considerably after the second dose. Therefore, monitoring of temperature and measures to lower the fever (such as antipyretic medication as seems clinically necessary) are recommended in young children (e.g. up to approximately 6 years of age) after each dose of Pandemrix.

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Epidemiological studies relating to Pandemrix in several European countries have indicated a five to 14-fold increased risk of narcolepsy with or without cataplexy in vaccinated as compared with unvaccinated children/adolescents, corresponding to an absolute risk ranging from three to seven additional cases in 100 000 vaccinated subjects. This risk increase has not been found in adults (older than 20 years).

The relationship between Pandemrix and narcolepsy is still under investigation.

In persons under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary. (see section 4.8)

4.5 Interaction with other medicinal products and other forms of interaction

Data obtained on co-administration of Pandemrix (H1N1)v with non-adjuvanted seasonal influenza vaccine (Fluarix, a split virion vaccine) in healthy adults aged over 60 years did not suggest any significant interference in the immune response to Pandemrix (H1N1)v. The immune response to Fluarix was satisfactory.

Co-administration was not associated with higher rates of local or systemic reactions compared to administration of Pandemrix alone.

Therefore the data indicate that Pandemrix may be co-administered with non-adjuvanted seasonal influenza vaccines (with injections made into opposite limbs).

Data obtained on the administration of a non-adjuvanted seasonal influenza vaccine (Fluarix, as above) three weeks before a dose of Pandemrix (H1N1)v in healthy adults over 60 years of age, did not suggest any significant interference in the immune response to Pandemrix (H1N1)v. Therefore the data indicate that Pandemrix may be administered three weeks after the administration of non-adjuvanted seasonal influenza vaccines.

In a clinical study where a non-adjuvanted seasonal influenza vaccine (Fluarix, as above) was administered 3 weeks after the second dose of Pandemrix (two doses were given 21 days apart), a lower immune response to Fluarix was observed as compared to subjects who had not previously received Pandemrix. It is not known whether the observed effects would apply to administration of non-adjuvanted seasonal influenza vaccine after a single dose of Pandemrix or when longer dose intervals have elapsed since administration of Pandemrix. It is preferable that non-adjuvanted seasonal influenza vaccines should be administered before or with the first dose of Pandemrix.

There are no data on co-administration of Pandemrix with other vaccines.

If co-administration with another vaccine is considered, immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.

The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.

Following influenza vaccination, false-positive serology test results may be obtained by the ELISA method for antibody to human immunodeficiency virus-1 (HIV-1), hepatitis C virus and, especially, HTLV-1. In such cases, the Western blot method is negative. These transitory false-positive results may be due to IgM production in response to the vaccine.

4.6 Fertility, pregnancy and lactation

Pregnancy

Pandemrix has been administered to women in each trimester of pregnancy. Information on outcomes from estimated more than 200,000 women who have been vaccinated during pregnancy is currently limited. There was no evidence of an increased risk of adverse outcomes in over 100 pregnancies that were followed in a prospective clinical study.

Animal studies with Pandemrix do not indicate reproductive toxicity (see section 5.3).

Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.

Breast-feeding

Pandemrix may be administered in lactating women.

Fertility

No fertility data are available.

4.7 Effects on ability to drive and use machines

Some of the effects mentioned under section 4.8 “Undesirable Effects” may affect the ability to drive or use machines.

4.8 Undesirable effects

Summary of the safety profile

Clinical studies have evaluated the incidence of adverse reactions in more than 1,000 subjects 18 years old and above who received Pandemrix (H1N1).

In adults 18 to 60 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (87.8%), fatigue (32.9%), headache (28.1%), arthralgia (17.9%), myalgia (30.0%), shivering (19.4%), injection site swelling (11.5%) and sweating (11.3%).

In subjects > 60 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (59.0%), myalgia (20.6%), fatigue (17.9%), headache (17.6%) and arthralgia (14.3%).

Tabulated list of adverse reactions

Adverse reactions reported are listed per dose according to the following frequency:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class

Frequency

Adverse reactions

Clinical trials

Blood and lymphatic system disorders

Uncommon

Lymphadenopathy

Psychiatric disorders

Uncommon

Insomnia

Nervous system disorders

Very common

Headache

Uncommon

Paraesthesia, dizziness

Gastrointestinal disorders

Common

Gastrointestinal symptoms (such as diarrhoea, vomiting, abdominal pain, nausea)

Skin and subcutaneous tissue disorders

Very common

Sweating increased

Uncommon

Pruritus, rash

Musculoskeletal and connective tissue disorders

Very common

Arthralgia, myalgia

General disorders and administration site conditions

Very common

Swelling and pain at the injection site, fatigue, shivering

Common

Redness and pruritus at the injection site, fever

Uncommon

induration and warmth at the injection site, influenza like illness, malaise

Post-marketing experience with Pandemrix (H1N1)v

Immune system disorders

 

Anaphylaxis, allergic reactions

Nervous system disorders

 

Febrile convulsions

Very rare1

Narcolepsy2 with or without cataplexy (see section 4.4)

 

Somnolence3

Skin and subcutaneous tissue disorders

 

Angioedema, generalised skin reactions, urticaria

General disorders and administration site conditions

 

Injection site reactions (such as inflammation, mass, ecchymosis)

Post-marketing experience with trivalent seasonal influenza vaccines

Blood and lymphatic system disorders

Rare

Transient thrombocytopenia

Nervous system disorders

Rare

Neuralgia

Very rare

Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome

Vascular disorders

Very rare

Vasculitis with transient renal involvement

1frequency based on estimated attributable risk from epidemiological studies in several European countries (see section 4.4)

2 Reported in subjects below 20 years of age.

3Reported in patients with narcolepsy and as a temporary event following vaccination

In clinical studies that evaluated reactogenicity in adults aged 18 years and above who received two 0.5 ml doses of Pandemrix (H1N1)v, higher rates of general solicited symptoms (such as fatigue, headache, arthralgia, myalgia, shivering, sweating and fever) were observed after the second dose compared to the first dose.

Paediatric population

Children aged 10-17 years

In clinical studies that evaluated the reactogenicity in children 10 to 17 years of age who received either two 0.5 ml doses (adult dose) or two 0.25 ml doses (half adult dose) (21 days apart) of Pandemrix (H1N1)v, the per-dose frequency of the following adverse reactions was as shown in the table:

Adverse reactions

10-17 years

Half adult dose

Adult dose

Post dose 1

N=118

Post dose 2

N=117

Post dose 1

N=98

Post dose 2

N=93

Pain

73.7%

68.4%

92.9%

96.8%

Redness

22.9%

31.6%

21.4%

28.0%

Swelling

30.5%

25.6%

41.8%

53.8%

Shivering

20.3%

16.2%

14.3%

26.9%

Sweating

7.6%

6.8%

5.1%

7.5%

Fever >38°C

1.7%

5.1%

3.1%

9.7%

Fever >39°C

1.7%

1.7%

0.0%

1.1%

Arthralgia

9.3%

15.4%

26.5%

34.4%

Myalgia

22.0%

23.1%

34.7%

47.3%

Fatigue

28.0%

27.4%

40.8%

51.6%

Gastrointestinal

11.0%

12.0%

6.1%

6.5%

Headache

35.6%

35.0%

41.8%

53.8%

Children aged 3-9 years

In clinical studies that evaluated reactogenicity in children 3 to 5 and 6 to 9 years of age who received either two 0.25 ml doses (half adult dose) or two 0.5 ml doses (adult dose) (21 days apart) of Pandemrix (H1N1)v, the per-dose frequency of the following adverse reactions was as shown in the table:

Adverse reactions

3-5 years

6-9 years

Half adult dose

Adult dose

Half adult dose

Adult dose

Post dose 1

N=60

Post dose 2

N=56

Post dose 1

N=53

Post dose 2

N=52

Post dose 1

N=65

Post dose 2

N=63

Post dose 1

N=57

Post dose 2

N=57

Pain

60.0%

55.4%

75.5%

84.6%

63.1%

65.1%

94.7%

96.5%

Redness

26.7%

41.1%

28.3%

34.6%

23.1%

33.3%

24.6%

33.3%

Swelling

21.7%

28.6%

34.0%

30.8%

23.1%

25.4%

28.1%

45.6%

Shivering

13.3%

7.1%

3.8%

9.6%

10.8%

6.3%

7.0%

22.8%

Sweating

10.0%

5.4%

1.9%

7.7%

6.2%

7.9%

1.8%

7.0%

Fever >38°C

10.0%

14.3%

5.7%

32.6%

4.6%

6.4%

1.8%

12.3%

Fever >39°C

1.7%

5.4%

0.0%

3.8%

0.0%

3.2%

0.0%

1.8%

Diarrhoea

5.0%

5.4%

1.9%

5.8%

NA

NA

NA

NA

Drowsiness

23.3%

17.9%

15.1%

28.8%

NA

NA

NA

NA

Irritability

20.0%

26.8%

18.9%

26.9%

NA

NA

NA

NA

Loss of appetite

20.0%

17.9%

15.1%

32.7%

NA

NA

NA

NA

Arthralgia

NA

NA

NA

NA

15.4%

14.3%

14.0%

22.8%

Myalgia

NA

NA

NA

NA

16.9%

17.5%

22.8%

28.1%

Fatigue

NA

NA

NA

NA

27.7%

20.6%

35.1%

49.1%

Gastrointestinal

NA

NA

NA

NA

13.8%

7.9%

15.8%

14.0%

Headache

NA

NA

NA

NA

21.5%

20.6%

42.1%

45.6%

NA= not available

Children aged 6-35 months

In a clinical study that evaluated reactogenicity in children aged 6 to 35 months who received either two 0.25 ml doses (half adult dose) or two 0.5 ml doses (adult dose) (21 days apart) of Pandemrix (H1N1)v there was an increase in injection site reactions and general symptoms after the second dose compared to the first dose particularly in rates of axillary fever (>38°C). The per-dose frequency of the following adverse reactions was as shown in the table:

Adverse reactions

Half adult dose

Adult dose

Post dose 1

N=104

Post dose 2

N=104

Post dose 1

N=53

Post dose 2

N=52

Pain

35.6%

41.3%

58.5%

51.9%

Redness

18.3%

32.7%

32.1%

44.2%

Swelling

11.5%

28.8%

20.8%

32.7%

Fever (>38°C) axillary

6.8%

41.4%

7.6%

46.1%

Fever (>39°C) axillary

1.0%

2.9%

1.9%

17.3%

Drowsiness

16.3%

33.7%

20.8%

42.3%

Irritability

26.9%

43.3%

22.6%

51.9%

Loss of appetite

17.3%

39.4%

20.8%

50.0%

This medicinal product contains thiomersal (an organomercuric compound) as a preservative and therefore, it is possible that sensitisation reactions may occur (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

4.9 Overdose

No case of overdose has been reported.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Influenza vaccines, ATC Code: J07BB02.

Pharmacodynamic effects

Immune response to Pandemrix (H1N1)v

Adults aged 18-60 years

Two clinical studies evaluated the immunogenicity of Pandemrix in healthy subjects aged 18-60 years. All subjects received two doses of 0.5 ml 21 days apart, except in study D-Pan H1N1-008, in which half of the subjects received only one dose of 0.5 ml. The anti-HA antibody responses were as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

 

D-Pan H1N1-007

D-Pan H1N1-008

21 days after 1st dose

21 days after 2nd dose

21 days after 1st dose

21 days after 2nd dose

Total enrolled subjects

N=60

[95% CI]

Seronegative subjects prior to vaccination

N=37

[95% CI]

Total enrolled subjects

N=59

[95% CI]

Seronegative subjects prior to vaccination

N=37

[95% CI]

Total enrolled subjects

N=120

[95% CI]

Seronegative subjects prior to vaccination

N=76

[95% CI]

Total enrolled subjects

N=66

[95% CI]

Seronegative subjects prior to vaccination

N=42

[95% CI]

Seroprotection rate1

100%

[94.0; 100]

100%

[90.5;100]

100%

[93.9; 100]

100%

[90.5;100]

97.5%

[92.9; 99.5]

96.1%

[88.9;99.2]

100%

[94.6; 100]

100%

[91.6;100]

Seroconversion rate2

98.3%

[91.1; 100]

100%

[90.5; 100]

98.3%

[90.9; 100]

100%

[90.5;100]

95.0%

[89.4; 98.1]

96.1%

[88.9;99.2]

98.5%

[91.8; 100]

100%

[91.6;100]

Seroconversion factor3

38.1

47.0

72.9

113.3

42.15

[33.43; 53.16]

50.73

[37.84; 68.02]

69.7

[53.79; 90.32]

105.9

[81.81;137.08]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

Six months after the first dose, the seroprotection rate was as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

D-Pan H1N1-007

D-Pan H1N1-008

Month 6 after 2 doses of 0.5 ml

Month 6 after 2 doses of 0.5 ml

Month 6 after 1 dose of 0.5 ml

 

Total enrolled subjects

N=59

[95% CI]

Seronegative subjects prior to vaccination

N=35

[95% CI]

Total enrolled subjects

N=67

[95% CI]

Seronegative subjects prior to vaccination

N=43

[95% CI]

Total enrolled subjects

N=51

[95% CI]

Seronegative subjects prior to vaccination

N=32

[95% CI]

Seroprotection rate1

100%

[93.9;100]

100%

[90.0;100]

97.0%

[89.6;99.6]

95.3%

[84.2;99.4]

86.3%

[73.7;94.3]

78.1%

[60.0;90.7]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

Twelve months after the first dose, the seroprotection rate was as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

D-Pan H1N1-007

D-Pan H1N1-008

Month 12 after 2 doses of 0.5 ml

Month 12 after 2 doses of 0.5 ml

Month 12 after 1 dose of 0.5 ml

 

Total enrolled subjects

N=59

[95% CI]

Seronegative subjects prior to vaccination

N=36

[95% CI]

Total enrolled subjects

N=67

[95% CI]

Seronegative subjects prior to vaccination

N=43

[95% CI]

Total enrolled subjects

N=52

[95% CI]

Seronegative subjects prior to vaccination

N=32

[95% CI]

Seroprotection rate1

78.0%

[65.3;87.7]

66.7%

[49.8;80.9]

79.1%

[67.4;88.1]

69.8%

[53.9;82.8]

65.4%

[50.9;78.0]

53.1%

[34.7;70.9]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

In study D-Pan-H1N1-008, the neutralising antibody responses were as follows:

Serum neutralising antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

After 2 doses of 0.5 ml

After 1 dose of 0.5 ml

 

Day 21

N=22

Day 42

N=22

Month 6

N=22

Day 21

N=17

Day 42

N=17

Month 6

N=17

Vaccine Response Rate2

68.2%

[45.1;86.1]

90.9%

[70.8;98.9]

81.8%

[59.7;94.8]

70.6%

[44.0;89.7]

64.7%

[38.3;85.8]

35.3%

[14.2;61.7]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Elderly (>60 years)

The anti-HA antibody responses in healthy subjects aged >60 years who received either one or two doses of 0.5 ml 21 days apart were as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

61-70 years

71-80 years

21 days after 1st dose

21 days after 2nd dose

21 days after 1st dose

21 days after 2nd dose

Total enrolled subjects

N=75

[95% CI]

Seronegative subjects prior to vaccination

N=43

[95% CI]

Total enrolled subjects

N=40

[95% CI]

Seronegative subjects prior to vaccination

N=23

[95% CI]

Total enrolled subjects

N=40

[95% CI]

Seronegative subjects prior to vaccination

N=23

[95% CI]

Total enrolled subjects

N=24

[95% CI]

Seronegative subjects prior to vaccination

N=15

[95% CI]

Seroprotection rate1

88.0%

[78.4; 94.4]

81.4%

[66.6;91.6]

97.5%

[86.8; 99.9]

95.7%

[78.1;99.9]

87.5%

[73.2; 95.8]

82.6%

[61.2;95.0]

100%

[85.8; 100]

100%

[78.2;100]

Seroconversion rate2

80.0%

[69.2; 88.4]

81.4%

[66.6;91.6]

95.0%

[83.1; 99.4]

95.7%

[78.1;99.9]

77.5%

[61.5; 89.2]

82.6%

[61.2;95.0]

91.7%

[73.0; 99.0]

100%

[78.2;100]

Seroconversion factor3

13.5

[10.3; 17.7]

20.3

[13.94; 28.78]

37.45

[25.29; 55.46]

62.06

[42.62; 90.37]

13.5

[8.6; 21.1]

20.67

[11.58; 36.88]

28.95

[17.02; 49.23]

50.82

[32.97; 78.35]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

>80 years

21 days after 1st dose

21 days after 2nd dose

Total enrolled subjects

N=5

[95% CI]

Seronegative subjects prior to vaccination

N=3

[95% CI]

Total enrolled subjects

N=3

[95% CI]

Seronegative subjects prior to vaccination

N=1

[95% CI]

Seroprotection rate1

80.0%

[28.4;99.5]

66.7%

[9.4;99.2]

100%

[29.2;100]

100%

[2.5;100]

Seroconversion rate2

80.0%

[28.4;99.5]

66.7%

[9.4;99.2]

100%

[29.2;100]

100%

[2.5;100]

Seroconversion factor3

18.4

[4.3;78.1]

17.95

[0.55;582.25]

25.49

[0.99;654.60]

64.0

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

Six months after the first dose, the seroprotection rate was as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

61-70 years

71-80 years

Month 6 after 2 doses of 0.5 ml

Month 6 after 1 dose of 0.5 ml

Month 6 after 2 doses of 0.5 ml

Month 6 after 1 dose of 0.5 ml

 

Total enrolled subjects

N=41

[95% CI]

Seronegative subjects prior to vaccination

N=23

[95% CI]

Total enrolled subjects

N=33

[95% CI]

Seronegative subjects prior to vaccination

N=19

[95% CI]

Total enrolled subjects

N=24

[95% CI]

Seronegative subjects prior to vaccination

N=15

[95% CI]

Total enrolled subjects

N=15

[95% CI]

Seronegative subjects prior to vaccination

N=7

[95% CI]

Seroprotection rate1

92.7%

[80.1; 98.5]

91.3%

[72.0; 98.9]

51.5%

[33.5; 69.2]

31.6%

[12.6; 56.6]

83.3%

[62.6; 95.3]

73.3%

[44.9; 92.2]

66.7%

[38.4; 88.2]

28.6%

[3.7; 71.0]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

>80 years

Month 6 after 2 doses of 0.5 ml

Month 6 after 1 dose of 0.5 ml

Total enrolled subjects

N=3

[95% CI]

Seronegative subjects prior to vaccination

N=1

[95% CI]

Total enrolled subjects2

N=2

[95% CI]

Seroprotection rate1

100%

[29.2;100]

100%

[2.5;100]

50.0%

[1.3;98.7]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

2all subjects seronegative prior to vaccination

Twelve months after the first dose, the seroprotection rate was as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

61-70 years

71-80 years

Month 12 after 2 doses of 0.5 ml

Month 12 after 1 dose of 0.5 ml

Month 12 after 2 doses of 0.5 ml

Month 12 after 1 dose of 0.5 ml

 

Total enrolled subjects

N=40

[95% CI]

Seronegative subjects prior to vaccination

N=23

[95% CI]

Total enrolled subjects

N=33

[95% CI]

Seronegative subjects prior to vaccination

N=19

[95% CI]

Total enrolled subjects

N=25

[95% CI]

Seronegative subjects prior to vaccination

N=16

[95% CI]

Total enrolled subjects

N=15

[95% CI]

Seronegative subjects prior to vaccination

N=7

[95% CI]

Seroprotection rate1

55.0%

[38.5;70.7]

34.8%

[16.4;57.3]

39.4%

[22.9;57.9]

21.1%

[6.1;45.6]

48.0%

[27.8;68.7]

25.0%

[7.3;52.4]

53.3%

[26.6;78.7]

14.3%

[0.4;57.9]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

 

>80 years

 

Month 12 after 2 doses of 0.5 ml

Month 12 after 1 dose of 0.5 ml

 

Total enrolled subjects

N=3

[95% CI]

Seronegative subjects prior to vaccination

N=1

[95% CI]

Total enrolled subjects2

N=2

[95% CI]

Seroprotection rate1

100%

[29.2;100]

100%

[2.5;100]

50.0%

[1.3;98.7]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40

2all subjects seronegative prior to vaccination

The neutralising antibody responses in subjects >60 years were as follows:

Serum neutralising antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

After 2 doses of 0.5 ml

After 1 dose of 0.5 ml

 

Day 21

N=22

Day 42

N=22

Month 6

N=22

Day 21

N=18

Day 42

N=18

Month 6

N=18

Vaccine Response Rate2

68.2%

[45.1;86.1]

86.4%

[65.1;97.1]

63.6%

[40.7;82.8]

33.3%

[13.3;59.0]

27.8%

[9.7;53.5]

38.9%

[17.3;64.3]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Paediatric population

Children aged 10-17 years

Two clinical studies evaluated the administration of a half (0.25 ml) dose and a full (0.5 ml) adult dose of Pandemrix in healthy children 10 to 17 years of age. The anti-HA antibody responses 21 days after the first and the second dose were as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

Half dose

(D-Pan-H1N1-023)

Full dose

(D-Pan-H1N1-010)

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Post dose 1

N=54

Post dose 2

N=54

Post dose 1

N=37

Post dose 2

N=37

Post dose 1

N=92

Post dose 2

N=88

Post dose 1

N=59

Post dose 2

N=57

Seroprotection rate1

98.1%

[90.1; 100]

100%

[93.4; 100]

97.3%

[85.8; 99.9]

100%

[90.5; 100]

100%

[96.1; 100]

100%

[95.9; 100]

100%

[93.9; 100]

100%

[93.7; 100]

Seroconversion rate2

96.3%

[87.3; 99.5]

98.1%

[90.1; 100]

97.3%

[85.8; 99.9]

100%

[90.5; 100]

96.7%

[90.8; 99.3]

96.6%

[90.4; 99.3]

100%

[93.9; 100]

100%

[93.7; 100]

Seroconversion factor3

48.29

[35.64; 65.42]

107.74

[76.64; 151.45]

67.7

[49.21; 93.05

187.92

[150.67; 234.38]

72.2

[57.2; 91.2]

139.1

[105.7; 183.1]

99.4

[81.0; 122.1]

249.8

[212.9; 293.2]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4according to protocol

The Day 180 seroprotection rate in the children who had received two half (0.25 ml) doses was 100%.

Twelve months after the first dose, the seroprotection rates in the children who had received two half (0.25 ml) doses were 90.2% and 100% in those who had received two full (0.5 ml) adult doses.

The neutralising antibody responses were as follows:

Serum neutralising antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

Half dose

Full dose

 

Post dose 1

N=13

Post dose 2

N=14

Month 6

N=13

Post dose 1

N=30

Post dose 2

N=29

Month 12

N=28

Vaccine Response Rate2

69.2%

[38.6;90.9]

100%

[76.8;100]

92.3%

[64.0;99.8]

86.7%

[69.3;96.2]

100%

[88.1;100]

89.3%

[71.8;97.7]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Children aged 3 to 9 years

In two clinical studies in which children aged 3 to 9 years old received two 0.25 ml doses (half adult dose) or two 0.5 ml doses (adult dose) of Pandemrix, the anti-HA antibody responses 21 days after the first and the second dose were as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

3-5 years

Half adult dose

(D-Pan-H1N1-023)

Adult dose5

(D-Pan-H1N1-010)

Total subjects4

N=28

[95% CI]

Seronegative subjects prior to vaccination

N=26

[95% CI]

Total subjects4

N=51

[95% CI]

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Seroprotection rate1

100%

[87.7;100]

100%

[87.7;100]

100%

[86.8;100]

100%

[86.8;100]

100%

[93.0;100]

100%

[93.0;100]

Seroconversion rate2

100%

[87.7;100]

100%

[87.7;100]

100%

[86.8;100]

100%

[86.8;100]

100%

[93.0;100]

100%

[93.0;100]

Seroconversion factor3

33.62

[26.25;43.05]

237.68

[175.28;322.29]

36.55

[29.01;46.06]

277.31

[223.81; 343.59]

49.1

[41.9;57.6]

384.9

[336.4;440.3]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4according to protocol

5all subjects seronegative prior to vaccination

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

6-9 years

Half adult dose

(D-Pan-H1N1-023)

Adult dose

(D-Pan-H1N1-010)

Total subjects4

N=30

[95% CI]

Seronegative subjects prior to vaccination

N=29

[95% CI]

Total subjects4

N=55

[95% CI]

Seronegative subjects prior to vaccination

N=48

[95% CI]

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Seroprotection rate1

100%

[88.4; 100]

100%

[88.4; 100]

100%

[88.1; 100]

100%

[88.1; 100]

100%

[93.5; 100]

100%

[93.5; 100]

100%

[92.6; 100]

100%

[92.6; 100]

Seroconversion rate2

100%

[88.4; 100]

100%

[88.4; 100]

100%

[88.1; 100]

100%

[88.1; 100]

100%

[93.5; 100]

100%

[93.5; 100]

100%

[92.6; 100

100%

[92.6; 100

Seroconversion factor3

36.33

[27.96; 47.22]

185.25

[142.09; 241.52]

37.7

[28.68; 48.71]

196.81

[154.32; 251.00]

59.0

[48.3; 72.0]

225.7

[182.7; 278.2]

61.7

[49.9; 76.3]

283.2

[246.0; 326.0]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4according to protocol

The Day 180 seroprotection rate in the children who had received two half (0.25 ml) doses was 100% in both age groups. Twelve months after the first dose, the seroprotection rate was 85% in both age groups. In the children who had received two adult (0.5 ml) doses, the seroprotection rates twelve months after the first dose were 100% for children aged 3-5 years and 98.0% for those aged 6-9 years.

The neutralising antibody responses were as follows:

Serum neutralising antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

3-5 years

 

Half adult dose

Adult dose

 

Post dose 1

N=16

Post dose 2

N=15

Month 6

N=16

Post dose 1

N=32

Post dose 2

N=29

Month 12

N=24

Vaccine Response Rate2

50.0%

[24.7; 75.3]

100%

[78.2; 100]

100%

[79.4; 100]

81.3%

[63.6; 92.8]

100%

[88.1; 100]

100%

[85.8; 100]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Serum neutralising antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

6-9 years

 

Half adult dose

Adult dose

 

Post dose 1

N=14

Post dose 2

N=15

Month 6

N=15

Post dose 1

N=37

Post dose 2

N=37

Month 12

N=31

Vaccine Response Rate2

71.4%

[41.9; 91.6]

100%

[78.2; 100]

93.3%

[68.1; 99.8]

86.7%

[69.3; 96.2]

100%

[88.1; 100]

96.8%

[83.3; 99.1]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Children aged 6-35 months

In a clinical study (D-Pan-H1N1-009) in healthy children 6 months to 35 months of age (stratified in ranges from 6 to 11, 12 to 23 and 24-35 months of age) the anti-HA antibody responses 21 days after a first and a second half adult dose (i.e. 0.25 ml) or adult dose (i.e. 0.5 ml) of Pandemrix were as follows:

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

6-11 months

Half adult dose

Adult dose

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

N=34

N = 32

N=30

N=28

N=15

N=15

N=14

N=14

Seroprotection rate1

100%

[89.7; 100]

100%

[89.1; 100]

100%

[88.4; 100]

100%

[87.7; 100]

100%

[78.2; 100]

100%

[78.2; 100]

100%

[76.8; 100]

100%

[76.8; 100]

Seroconversion rate2

97.1%

[84.7; 99.9]

100%

[89.1; 100]

100

[88.4; 100]

100%

[87.7; 100]

100%

[78.2; 100]

100%

[78.2; 100]

100%

[76.8; 100]

100%

[76.8; 100]

Seroconversion factor3

48.12

[34.34; 67.42]

276.14

[164.23; 455.99]

64.0

[52.3; 78.3]

441.3

[365.7; 532.6]

46.29

[38.83; 59.80]

370;48

[217,97; 629,69]

49.9

[40.3; 61.9]

452.4

[322.4; 634.6]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4according to protocol

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

12-23 months

Half adult dose

Adult dose

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Total subjects4

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

N=34

N= 32

N=33

N=31

N=16

N=17

N=15

N=16

Seroprotection rate1

100%

[89.7; 100]

100%

[89.1; 100]

100%

[89.4; 100]

100%

[88.8; 100]

100%

[79.4; 100]

100%

[80.5; 100]

100%

[78.2; 100]

100%

[79.4; 100]

Seroconversion rate2

100%

[89.7; 100]

100%

[89.1; 100]

100%

[89.4; 100]

100%

[88.8; 100]

100%

[79.4; 100]

100%

[80.5; 100]

100%

[78.2; 100]

100%

[79.4; 100]

Seroconversion factor3

63.37

[48.13; 83.43]

386.45

[308.54; 484.02]

66.7

[51.4; 86.7]

404.8

[327.8; 500.0]

64.06

[38.55; 106.44]

472.16

[343.74; 648.57]

75.3

[50.3; 112.5]

523.2

[408.5; 670.1]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4according to protocol

anti-HA antibody

Immune response to A/California/7/2009 (H1N1)v-like

24-35 months

Half adult dose4

Adult dose

Total subjects5

[95% CI]

Total subjects5

[95% CI]

Seronegative subjects prior to vaccination

[95% CI]

Post dose 1

Post dose 2

Post dose 1

Post dose 2

Post dose 1

Post dose 2

N=33

N= 33

N=16

N=16

N=12

N=12

Seroprotection rate1

100%

[89.4; 100]

100%

[89.4; 100]

100%

[79.4;100]

100%

[79.4;100]

100%

[73.5;100]

100%

[73.5;100]

Seroconversion rate2

100%

[89.4; 100]

100%

[89.4; 100]

93.8

[69.8;99.8]

100%

[79.4;100]

100%

[73.5;100]

100%

[73.5;100]

Seroconversion factor3

52.97

[42.08;66.68]

389.64

[324.25; 468.21]

33.44

[18.59;60.16]

189.16

[83.80; 427.01]

55.4

[39.8;77.2]

406.4

[296.2;557.4]

1 seroprotection rate: proportion of subjects with haemagglutination inhibition (HI) titre ≥1:40;

2seroconversion rate: proportion of subjects who were either seronegative at pre-vaccination and have a protective post-vaccination titre of ≥1:40, or who were seropositive at pre-vaccination and have a 4-fold increase in titre;

3seroconversion factor: ratio of the post-vaccination geometric mean titre (GMT) and the pre-vaccination GMT.

4all subjects seronegative prior to vaccination

5according to protocol

Twelve months after the first dose, the seroprotection rate was 100% in all age groups and dosage groups.

The clinical relevance of the haemagglutination inhibition (HI) titre ≥1:40 in children is unknown.

The neutralising antibody responses were as follows:

Serum neutrali-sing antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

6-11 months

 

Half dose

Adult dose

 

Post dose 1

N=28

Post dose 2

N=28

Month 12

N=22

Post dose 1

N=14

Post dose 2

N=14

Month 12

N=10

Vaccine Response Rate2

57.1%

[37.2; 75.5]

96.4%

[81.7; 99.9]

86.4%

[65.1; 97.1]

57.1%

[28.9; 82.3]

100%

76.8; 100]

100%

[69.2; 100]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Serum neutrali-sing antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

12-23 months

 

Half dose

Adult dose

 

Post dose 1

N=14

Post dose 2

N=16

Month 12

N=13

Post dose 1

N=7

Post dose 2

N=8

Month 12

N=7

Vaccine Response Rate2

57.1%

[28.9;82.3]

100%

[79.4;100]

92.3%

[64.0;99.8]

71.4%

[29.0;96.3]

100%

[63.1;100]

100%

[59.0;100]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

Serum neutrali-sing antibody

Immune response to A/Netherlands/602/9 (H1N1)v-like1

 

24-35 months

 

Half dose

Adult dose

 

Post dose 1

N=17

Post dose 2

N=17

Month 12

N=14

Post dose 1

N=8

Post dose 2

N=7

Month 12

N=5

Vaccine Response Rate2

58.8%

[32.9;81.6]

100%

[80.5;100]

100%

[76.8;100]

62.5%

[24.5;91.5]

100%

[59.0;100]

100%

[47.8;100]

1antigenically similar to A/California/7/2009 (H1N1)v-like

2percentage of vaccinees who, if initially seronegative reach an antibody titre ≥32 1/DIL after vaccination or, if initially seropositive reach an antibody titre ≥ 4-fold the pre-vaccination antibody titre

The European Medicines Agency has deferred the obligation to submit the results of studies with Pandemrix in one or more subsets of the paediatric population in the prevention of influenza infection (see section 4.2 for information on paediatric use).

Information from non-clinical studies:

The ability to induce protection against homologous and heterologous vaccine strains was assessed non-clinically using ferret challenge models.

In each experiment, four groups of six ferrets were immunized intramuscularly with an AS03 adjuvanted vaccine containing HA derived from H5N1/A/Vietnam/1194/04 (NIBRG-14). Doses of 15, 5, 1.7 or 0.6 micrograms of HA were tested in the homologous challenge experiment, and doses of 15, 7.5, 3.8 or 1.75 micrograms of HA were tested in the heterologous challenge experiment. Control groups included ferrets immunized with adjuvant alone, non-adjuvanted vaccine (15 micrograms HA) or phosphate buffered saline solution. Ferrets were vaccinated on days 0 and 21 and challenged by the intra-tracheal route on day 49 with a lethal dose of either H5N1/A/Vietnam/1194/04 or heterologous H5N1/A/Indonesia/5/05. Of the animals receiving adjuvanted vaccine, 87% and 96% were protected against the lethal homologous or heterologous challenge, respectively. Viral shedding into the upper respiratory tract was also reduced in vaccinated animals relative to controls, suggesting a reduced risk of viral transmission. In the unadjuvanted control group, as well as in the adjuvant control group, all animals died or had to be euthanized as they were moribund, three to four days after the start of challenge.

Additional information is available from the studies conducted with a vaccine similar in composition to Pandemrix but containing antigen derived from H5N1 viruses. Please consult the Product Information of Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted).

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Non-clinical data obtained with the mock-up vaccine using a H5N1 vaccine strain reveal no special hazard for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity, local tolerance, female fertility, embryo-fetal and postnatal toxicity (up to the end of the lactation period).

6. Pharmaceutical particulars
6.1 List of excipients

Suspension vial:

Polysorbate 80

Octoxynol 10

Thiomersal

Sodium chloride (NaCl)

Disodium hydrogen phosphate (Na2HPO4)

Potassium dihydrogen phosphate (KH2PO4)

Potassium chloride (KCl)

Magnesium chloride (MgCl2)

Water for injections

Emulsion vial:

Sodium chloride (NaCl)

Disodium hydrogen phosphate (Na2HPO4)

Potassium dihydrogen phosphate (KH2PO4)

Potassium chloride (KCl)

Water for injections

For adjuvants, see section 2.

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

2 years.

After mixing, the vaccine should be used within 24 hours. Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after mixing of the medicinal product, see section 6.3.

6.5 Nature and contents of container

One pack containing:

- one pack of 50 vials (type I glass) of 2.5 ml suspension with a stopper (butyl rubber).

- two packs of 25 vials (type I glass) of 2.5 ml emulsion with a stopper (butyl rubber).

The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to 10 doses of vaccine (5 ml).

6.6 Special precautions for disposal and other handling

Pandemrix consists of two containers:

Suspension: multidose vial containing the antigen,

Emulsion: multidose vial containing the adjuvant.

Prior to administration, the two components should be mixed.

Instructions for mixing and administration of the vaccine:

1. Before mixing the two components, the emulsion (adjuvant) and suspension (antigen) should be brought to room temperature (allow a minimum of 15 minutes); each vial should be shaken and inspected visually for any foreign particulate matter and/or abnormal physical appearance. In the event of either being observed (including rubber particles from the stopper), discard the vaccine.

2. The vaccine is mixed by withdrawing the entire contents of the vial containing the adjuvant by means of a 5 ml syringe and by adding it to the vial containing the antigen. It is recommended to equip the syringe with a 23-G needle. However, in the case this needle size would not be available, a 21-G needle might be used. The vial containing the adjuvant should be maintained in upside down position to facilitate the withdrawal of the full content.

3. After the addition of the adjuvant to the antigen, the mixture should be well shaken. The mixed vaccine is a whitish emulsion. In the event of other variation being observed, discard the vaccine.

4. The volume of the Pandemrix vial after mixing is at least 5 ml. The vaccine should be administered in accordance with the recommended posology (see section 4.2).

5. The vial should be shaken prior to each administration and inspected visually for any foreign particulate matter and/or abnormal physical appearance. In the event of either being observed (including rubber particles from the stopper), discard the vaccine.

6. Each vaccine dose of 0.5 ml (full dose) or 0.25 ml (half dose) is withdrawn into a 1 ml syringe for injection and administered intramuscularly. It is recommended to equip the syringe with a needle gauge not larger than 23-G.

7. After mixing, use the vaccine within 24 hours. The mixed vaccine can either be stored in a refrigerator (2°C - 8°C) or at room temperature not exceeding 25°C. If the mixed vaccine is stored in a refrigerator, it should be brought to room temperature (allow a minimum of 15 minutes) before each withdrawal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

GlaxoSmithKline Biologicals s.a.

rue de l'Institut 89

B-1330 Rixensart, Belgium

8. Marketing authorisation number(s)

EU/1/08/452/001

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 20 May 2008

10. Date of revision of the text

25/07/2013

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.

Company contact details

GlaxoSmithKline UK

Company image
Address

Stockley Park West, Uxbridge, Middlesex, UB11 1BT

Fax

+44 (0)208 990 4328

Telephone

+44 (0)800 221 441

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

influenza vaccine (split virion, inactivated)

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue